Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 02, 2024

BUY
$4.98 - $6.77 $2,514 - $3,418
505 Added 4.62%
11,430 $68,000
Q1 2023

Jun 01, 2023

SELL
$7.94 - $11.84 $4,049 - $6,038
-510 Reduced 4.46%
10,925 $91.1 Million
Q1 2022

May 18, 2022

BUY
$11.56 - $19.76 $132,188 - $225,955
11,435 New
11,435 $186,000
Q1 2022

May 16, 2022

SELL
$11.56 - $19.76 $132,188 - $225,955
-11,435 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$11.18 - $15.46 $127,843 - $176,785
11,435 New
11,435 $158,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.45B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Golden State Equity Partners Portfolio

Follow Golden State Equity Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

News

Stay updated on Golden State Equity Partners with notifications on news.